Malignancy Rate of Bethesda Class III Thyroid Nodules Based on the Presence of Chronic Lymphocytic Thyroiditis in Surgical Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Yoon Young | - |
dc.contributor.author | Chung, Yun Jae | - |
dc.contributor.author | Kim, Hee Sung | - |
dc.date.accessioned | 2022-06-03T02:40:11Z | - |
dc.date.available | 2022-06-03T02:40:11Z | - |
dc.date.issued | 2021-09 | - |
dc.identifier.issn | 1664-2392 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/20919 | - |
dc.description.abstract | Background Hashimoto's thyroiditis (HT), also known as chronic lymphocytic thyroiditis (CLT), may interfere with the accurate cytological diagnosis of thyroid nodules. Recently, HT has been considered a premalignant condition for thyroid cancer development. The diagnosis of atypia of undetermined significance/follicular lesions of undetermined significance (AUS/FLUS) thyroid nodules is challenging and evidence for the malignancy risk of AUS/FLUS thyroid nodules coexisting with CLT is scarce. Therefore, we assessed the malignancy risk of AUS/FLUS thyroid nodules according to the presence of background CLT.</p> Methods This study included 357 surgically resected thyroid nodules with AUS/FLUS cytology. Cases with concomitant malignant nodules were excluded. CLT was defined based on the pathologic report after thyroid surgery.</p> Results Among 357 tumors, 130 tumors (36%) were confirmed to have coexisting CLT, and 170 tumors (48%) were determined to be malignant after thyroidectomy. Malignancy rates were similar in both groups (48% in each) regardless of background CLT (62/130 with CLT vs. 108/227 without CLT). In the group with CLT, thyroiditis was more frequent in the final pathology (12% with CLT vs. 1% without CLT, P = 0.003). In multivariate analysis, positive BRAF (V600E) mutation, highly suspicious sonographic features (K-TIRADS 5), and smaller thyroid nodules were significant factors for thyroid malignancies.</p> Conclusion The malignancy rate of thyroid nodules with AUS/FLUS cytology was comparable irrespective of the presence of underlying CLT.</p> | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Frontiers Media S.A. | - |
dc.title | Malignancy Rate of Bethesda Class III Thyroid Nodules Based on the Presence of Chronic Lymphocytic Thyroiditis in Surgical Patients | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3389/fendo.2021.745395 | - |
dc.identifier.scopusid | 2-s2.0-85117112887 | - |
dc.identifier.wosid | 000707763900001 | - |
dc.identifier.bibliographicCitation | Frontiers in Endocrinology, v.12, no.0, pp 1 - 7 | - |
dc.citation.title | Frontiers in Endocrinology | - |
dc.citation.volume | 12 | - |
dc.citation.number | 0 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 7 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | SYSTEM | - |
dc.subject.keywordAuthor | atypia of undetermined significance | - |
dc.subject.keywordAuthor | fine-needle aspiration | - |
dc.subject.keywordAuthor | chronic lymphocytic thyroiditis | - |
dc.subject.keywordAuthor | Hashimoto's thyroiditis | - |
dc.subject.keywordAuthor | thyroid malignancy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.